Trials / Withdrawn
WithdrawnNCT01469507
Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis
Comparative Study of Efficacy and Safety of Three Intra Articular Injections of V0220 Versus Hyalgan® in Patients Suffering From Symptomatic Knee Osteoarthritis. A Multinational Multicentric, Randomised, Double-blind, Parallel-group Study
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare a combination of hyaluronic acid and chondroitin sulfate (V0220) to Hyalgan® on pain relief in patients with symptomatic knee osteoarthritis (OA) over 24 weeks when administered in three weekly injections. Chondroitin sulfate is one of the components of cartilage. Studies have shown that chondroitin sulphate improves the quality of the hyaluronic acid produced in the joint. The benefit of V0220 combination is based on two main physicochemical properties, in line with the characteristics of osteoarthritic disease: optimising the rheological behaviour and improving the buffering effect on synovial flow ("outflow buffering").
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Chondroitin sulfate and sodium hyaluronate | 3 weekly injections |
| DRUG | Hyaluronan | 3 weekly injections |
Timeline
- First posted
- 2011-11-10
- Last updated
- 2013-02-21
Source: ClinicalTrials.gov record NCT01469507. Inclusion in this directory is not an endorsement.